» Articles » PMID: 7721806

The Human 180-kDa Receptor for Secretory Phospholipases A2. Molecular Cloning, Identification of a Secreted Soluble Form, Expression, and Chromosomal Localization

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1995 Apr 14
PMID 7721806
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Secretory phospholipases A2 (sPLA2) are structurally related enzymes found in mammals as well as in insect and snake venoms. They have been associated with several physiological, pathological, and toxic processes. Some of these effects are apparently linked to the existence of specific receptors for both venom and mammalian sPLA2s. We report here the molecular cloning and expression of one of these sPLA2 receptors from human kidney. Two transcripts were detected. One encodes for a transmembrane form of the sPLA2 receptor and the other one is an alternatively processed transcript, caused by polyadenylation occurring at a site within an intron in the C terminus part of the transcriptional unit. This transcript encodes for a shortened secreted soluble sPLA2 receptor lacking the coding region for the transmembrane segment. Quantitative polymerase chain reaction experiments indicate a 1.6:1 ratio between the levels of transcripts encoding for the membrane-bound and soluble forms of the receptor, respectively. Soluble and membrane-bound human sPLA2 receptors both bind sPLA2 with high affinities. However, the binding properties of the human receptors are different from those obtained with the rabbit membrane-bound sPLA2 receptor. The 180-kDa human sPLA2 receptor gene has been mapped in the q23-q24 bands of chromosome 2.

Citing Articles

PM2.5-induced oxidative stress upregulates PLA2R expression in the lung and is involved in the pathogenesis of membranous nephropathy through extracellular vesicles.

Zhang W, Chen J, Yuan Y, Luo J, Zhou Z, Wang G Front Pharmacol. 2025; 15:1516111.

PMID: 39744137 PMC: 11688400. DOI: 10.3389/fphar.2024.1516111.


The fate of immune complexes in membranous nephropathy.

Xu J, Hu H, Sun Y, Zhao Z, Zhang D, Yang L Front Immunol. 2024; 15:1441017.

PMID: 39185424 PMC: 11342396. DOI: 10.3389/fimmu.2024.1441017.


Membranous nephropathy: pathogenesis and treatments.

Wang M, Yang J, Fang X, Lin W, Yang Y MedComm (2020). 2024; 5(7):e614.

PMID: 38948114 PMC: 11214595. DOI: 10.1002/mco2.614.


The co-occurrence of sarcoidosis and anti-PLA2R-associated membranous nephropathy in a patient with underlying genetic susceptibility.

Ding Y, Yao Y, Wan L, Qu Z, Yu F BMC Nephrol. 2024; 25(1):212.

PMID: 38937663 PMC: 11212182. DOI: 10.1186/s12882-024-03649-0.


Ectodomain shedding of PLA2R1 is mediated by the metalloproteases ADAM10 and ADAM17.

Dolla G, Nicolas S, Dos Santos L, Bourgeois A, Pardossi-Piquard R, Bihl F J Biol Chem. 2024; 300(7):107480.

PMID: 38897568 PMC: 11301074. DOI: 10.1016/j.jbc.2024.107480.